Anish Thomas

13.6k total citations · 4 hit papers
161 papers, 8.5k citations indexed

About

Anish Thomas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anish Thomas has authored 161 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 52 papers in Molecular Biology. Recurrent topics in Anish Thomas's work include Lung Cancer Research Studies (43 papers), Occupational and environmental lung diseases (34 papers) and Lung Cancer Treatments and Mutations (28 papers). Anish Thomas is often cited by papers focused on Lung Cancer Research Studies (43 papers), Occupational and environmental lung diseases (34 papers) and Lung Cancer Treatments and Mutations (28 papers). Anish Thomas collaborates with scholars based in United States, Japan and Germany. Anish Thomas's co-authors include Michael J. Thun, Ahmedin Jemal, Thomas S. Murray, Raffit Hassan, Beverly A. Teicher, Yves Pommier, Giuseppe Giaccone, Ira Pastan, Markku Miettinen and Arun Rajan and has published in prestigious journals such as Nature, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Anish Thomas

156 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer Statistics, 2002

2002 2.5k citations Anish Thomas et al. profile →
Antibody–drug conjugates for cancer therapy

2016 450 citations Anish Thomas, Raffit Hassan et al. profile →
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

2018 260 citations Hedy L. Kindler, Nofisat Ismaila et al. Journal of Clinical Oncology profile →
Cancer treatments: Past, present, and future

2024 192 citations Anish Thomas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anish Thomas United States	43	3.7k	2.9k	2.8k	983	926	161	8.5k
B. Nebiyou Bekele United States	56	3.8k 1.0×	3.3k 1.1×	3.9k 1.4×	1.4k 1.5×	577 0.6×	137	10.3k
Gérard Zalcman France	39	3.5k 0.9×	3.0k 1.0×	2.1k 0.8×	890 0.9×	678 0.7×	299	6.7k
Alain C. Mita United States	46	3.4k 0.9×	1.8k 0.6×	3.7k 1.3×	989 1.0×	837 0.9×	210	8.1k
Alain Borczuk United States	50	2.2k 0.6×	4.3k 1.5×	2.6k 0.9×	1.0k 1.1×	719 0.8×	181	8.6k
Bert H. O’Neil United States	47	5.7k 1.5×	2.0k 0.7×	2.5k 0.9×	1.3k 1.3×	863 0.9×	255	9.1k
Patrick Micke Sweden	45	3.5k 0.9×	2.0k 0.7×	3.1k 1.1×	1.6k 1.7×	1.5k 1.6×	162	8.0k
Jacques De Grève Belgium	44	3.4k 0.9×	1.8k 0.6×	3.1k 1.1×	1.3k 1.3×	475 0.5×	264	8.3k
Taofeek K. Owonikoko United States	52	5.8k 1.6×	3.4k 1.2×	3.8k 1.3×	1.4k 1.4×	1.6k 1.7×	326	10.7k
Siqing Fu United States	51	4.1k 1.1×	2.4k 0.8×	3.8k 1.4×	2.4k 2.5×	954 1.0×	412	9.6k
Hal W. Hirte Canada	45	3.7k 1.0×	1.3k 0.4×	3.2k 1.1×	977 1.0×	1.0k 1.1×	156	8.1k

Countries citing papers authored by Anish Thomas

Since Specialization

Citations

This map shows the geographic impact of Anish Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anish Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anish Thomas more than expected).

Fields of papers citing papers by Anish Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anish Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anish Thomas. The network helps show where Anish Thomas may publish in the future.

Co-authorship network of co-authors of Anish Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Anish Thomas. A scholar is included among the top collaborators of Anish Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anish Thomas. Anish Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ireland, Abbie S., M. Weber, L. Zuo, et al.. (2025). Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer. Nature. 647(8088). 257–267. 4 indexed citations

Takahashi, Nobuyuki, Lőrinc Sándor Pongor, Vinodh N. Rajapakse, et al.. (2025). Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor. Genome Medicine. 17(1). 15–15. 2 indexed citations

Desai, Parth & Anish Thomas. (2025). 84P Targeting small cell lung cancer neuroendocrine heterogeneity via FGFR inhibition. ESMO Open. 10. 104243–104243.

Sun, Yilun, et al.. (2022). CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II. Molecular Cancer Therapeutics. 21(9). 1430–1438. 9 indexed citations

Thomas, Anish, Shaun D. Fontaine, Morgan E. Diolaiti, et al.. (2022). PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM -Deficient Tumors and Potent Synergy With PARP Inhibitors. Molecular Cancer Therapeutics. 21(11). 1722–1728. 7 indexed citations

Takahashi, Nobuyuki, Se Hyun Kim, Christopher W. Schultz, et al.. (2022). Replication Stress Defines Distinct Molecular Subtypes Across Cancers. Cancer Research Communications. 2(6). 503–517. 18 indexed citations

Takahashi, Nobuyuki, Ira Surolia, & Anish Thomas. (2020). Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation. Clinical Cancer Research. 26(11). 2452–2456. 10 indexed citations

Jiang, Qun, Azam Ghafoor, Idrees Mian, et al.. (2020). Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine. 12(550). 35 indexed citations

Hassan, Raffit, Evan Alley, Hedy L. Kindler, et al.. (2019). Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research. 25(19). 5787–5798. 88 indexed citations

10.

Alewine, Christine, Cody J. Peer, Zishuo I. Hu, et al.. (2019). Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research. 26(4). 828–836. 40 indexed citations

11.

Thomas, Anish & Yves Pommier. (2019). Targeting Topoisomerase I in the Era of Precision Medicine. Clinical Cancer Research. 25(22). 6581–6589. 195 indexed citations

12.

Khanna, Swati, Francis Mussai, Anish Thomas, et al.. (2018). Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research. 24(12). 2859–2872. 43 indexed citations

13.

Kindler, Hedy L., Nofisat Ismaila, Samuel G. Armato, et al.. (2018). Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 36(13). 1343–1373. 260 indexed citations breakdown →

14.

Tang, Sai-Wen, Anish Thomas, Junko Murai, et al.. (2018). Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors. Clinical Cancer Research. 24(8). 1944–1953. 65 indexed citations

15.

Mutti, Luciano, Tobias Peikert, B. W. Robinson, et al.. (2018). Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology. 13(9). 1269–1283. 69 indexed citations

16.

Hassan, Raffit, Hedy L. Kindler, Thierry Jahan, et al.. (2014). Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. Clinical Cancer Research. 20(23). 5927–5936. 139 indexed citations

17.

Thomas, Anish, Arun Rajan, Éva Szabó, et al.. (2014). A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research. 20(21). 5392–5402. 79 indexed citations

18.

Thomas, Anish, Esther Mena, Karen Kurdziel, et al.. (2013). 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors. Clinical Cancer Research. 19(6). 1487–1493. 19 indexed citations

19.

Thomas, Anish, Sudarsan Rajan, Syamalima Dube, et al.. (2010). Expression of a novel tropomyosin isoform in axolotl heart and skeletal muscle. Journal of Cellular Biochemistry. 110(4). 875–881. 26 indexed citations

20.

Thomas, Anish, Raisa Perzova, Lynn Abbott, et al.. (2010). LGL Leukemia and HTLV. AIDS Research and Human Retroviruses. 26(1). 33–40. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact